Geopolitical and macroeconomic uncertainties
Management cited external environment risks including shipping disruptions and US inflationary pressures, leading to conservative guidance.
medium · management_commentarySenores Pharmaceuticals Ltd — Q4 FY26
Senores Pharmaceuticals delivered a stellar Q4 FY26, with consolidated revenue of 190 crores (up 66% YoY) and EBITDA of 62 crores (up 3x YoY), driven by 83% growth in regulated...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Working capital days increase
Working capital days rose to 187 days in FY26 from 114 days in FY25, partly due to inventory buildup for new launches. Management expects normalization.
medium · analyst_questionUnbilled revenue buildup
Other financial assets (unbilled revenue) increased to 172 crores from 116 crores, reflecting profit share recognition before cash realization. Management expects plateauing.
low · analyst_questionExecution risk on ANDA commercialization
30 approved ANDAs are yet to be launched; delays in commercialization could impact revenue visibility.
medium · data_observation